
Afatinib
Afatinib is a medication used to treat a specific type of lung cancer called non-small cell lung cancer (NSCLC) that has specific genetic mutations. It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs) and works by blocking proteins involved in the growth of cancer cells. Afatinib is specifically used for NSCLC patients with mutations in the epidermal growth factor receptor (EGFR) gene. By inhibiting EGFR and related proteins, afatinib helps slow down or stop the growth of cancer cells.
synthesis of Afatinib

Afatinib Intermediate
At Hekmat Medicinal Chemistry Developments, we specialize in producing high-quality Afatinib Intermediate at a competitive price. With our expertise in medicinal chemistry and pharmaceutical development, we ensure that our intermediate meets stringent industry standards. Our focus on quality assurance, competitive pricing, regulatory compliance, and customer satisfaction sets us apart. Partner with us for reliable and effective Afatinib Intermediate for your pharmaceutical manufacturing needs.

| CAS No | 314771-76-1 |
| IUPAC Name | (S)-N4-(3-Chloro-4-fluorophenyl)-7-((tetrahydrofuran-3-yl)oxy)quinazoline-4,6-diamine |
| Synonyms | N4-(3-Chloro-4-fluorophenyl)-7-[[(3S)-tetrahydro-3-furanyl]oxy]-4,6-quinazolinediamine; (S)-N4-(3-Chloro-4-fluorophenyl)-7-((tetrahydrofuran-3-yl)oxy)quinazoline-4,6-diamine; Des(4-dimethylamino-2-en-1-oxo)butyl Afatin |
| Molecular Formula | C₁₈H₁₆ClFN₄O₂ |
| Molecular Weight | 374.8 |
